Evaluating Roivant Sciences: Insights From 6 Financial Analysts
Roivant Sciences (NASDAQ:ROIV) has been analyzed by 6 analysts in the last three months, revealing a diverse range…
The Analyst Verdict: Roivant Sciences In The Eyes Of 6 Experts
6 analysts have shared their evaluations of Roivant Sciences (NASDAQ:ROIV) during the recent three months, expressing a mix…
Vivek Ramaswamy Breathes New Life In Beaten Down BuzzFeed Stock: What’s Going On?
BuzzFeed shares surged after Vivek Ramaswamy acquired a 7.7% stake for $3.2 million.
Critical Insights From Roivant Sciences Analyst Ratings: What You Need To Know
7 analysts have expressed a variety of opinions on Roivant Sciences (NASDAQ:ROIV) over the past quarter, offering a…
Vivek Ramaswamy-Founded Roivant’s Anti-Inflammatory Drug Aces Mid-Stage Study
Roivant Sciences and Priovant Therapeutics report Phase 2 results for brepocitinib in treating non-anterior non-infectious uveitis. Week 24 data show promising efficacy, with lower treatment failure rates and positive secondary endpoints. Roivant authorizes a $1.5 billion share repurchase program
10 Health Care Stocks Whale Activity In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums…
5 Value Stocks In The Healthcare Sector
What is a Value Stock? A value stock is traditionally defined in terms of how investors in the…
The Analyst Landscape: 4 Takes On Roivant Sciences
Ratings for Roivant Sciences (NASDAQ:ROIV) were provided by 4 analysts in the past three months, showcasing a mix…
Earnings Scheduled For February 13, 2024
Companies Reporting Before The Bell
• LCI Indus (NYSE:LCII) is likely to report quarterly earnings at $0.18 per share on revenue of $838.27 million.
Roivant Sciences Earnings Preview
Roivant Sciences (NASDAQ:ROIV) is set to give its latest quarterly earnings report on Tuesday, 2024-02-13. Here’s what investors…